James William Rogers Sells 10,853 Shares of Tempus AI (NASDAQ:TEM) Stock

by · The Cerbat Gem

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) CFO James William Rogers sold 10,853 shares of the firm’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total transaction of $478,291.71. Following the completion of the transaction, the chief financial officer directly owned 126,395 shares in the company, valued at approximately $5,570,227.65. This represents a 7.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Trading Up 1.3%

Shares of TEM stock traded up $0.61 during mid-day trading on Thursday, reaching $46.49. The company’s stock had a trading volume of 3,802,434 shares, compared to its average volume of 5,629,236. Tempus AI, Inc. has a 12-month low of $41.73 and a 12-month high of $104.32. The company’s 50 day simple moving average is $49.11 and its 200-day simple moving average is $59.69. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. The firm has a market capitalization of $8.35 billion, a PE ratio of -27.03 and a beta of 3.99.

Tempus AI (NASDAQ:TEM – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The company had revenue of $348.12 million during the quarter, compared to the consensus estimate of $345.44 million. During the same quarter in the prior year, the business earned ($0.24) earnings per share. The company’s revenue was up 36.1% compared to the same quarter last year. On average, research analysts predict that Tempus AI, Inc. will post -1.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Tempus AI

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPL Wealth Management LLC purchased a new stake in Tempus AI during the 3rd quarter worth approximately $26,000. Los Angeles Capital Management LLC purchased a new stake in Tempus AI during the 4th quarter worth approximately $27,000. Harvest Fund Management Co. Ltd purchased a new stake in Tempus AI during the 3rd quarter worth approximately $38,000. Whittier Trust Co. increased its holdings in Tempus AI by 190.0% during the 1st quarter. Whittier Trust Co. now owns 870 shares of the company’s stock worth $41,000 after purchasing an additional 570 shares during the last quarter. Finally, Lodestone Wealth Management LLC purchased a new stake in Tempus AI during the 4th quarter worth approximately $42,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently issued reports on TEM. BTIG Research dropped their price objective on shares of Tempus AI from $90.00 to $80.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Robert W. Baird began coverage on shares of Tempus AI in a research note on Tuesday, February 17th. They set an “outperform” rating and a $59.00 price objective on the stock. Wall Street Zen lowered shares of Tempus AI from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Morgan Stanley dropped their price objective on shares of Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 3rd. Finally, HC Wainwright dropped their price objective on shares of Tempus AI from $95.00 to $64.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Tempus AI currently has an average rating of “Moderate Buy” and a consensus target price of $68.64.

Check Out Our Latest Report on Tempus AI

About Tempus AI

(Get Free Report)

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

Recommended Stories